Skip to main content
. Author manuscript; available in PMC: 2019 May 25.
Published in final edited form as: Hepatology. 2016 Dec 24;65(2):426–438. doi: 10.1002/hep.28901

TABLE 4.

SVR Rates Among Genotype 1 Patients Treated With 8 Versus 12 Weeks of LDV/SOF

White
SVR %
(95% CI)		 Black
SVR %
(95% CI)		 Hispanic
SVR %
(95% CI)		 Asian/AI/PI/AN
SVR %
(95% CI)		 Declined
SVR %
(95% CI)
LDV/SOF 8 weeks (n = 2,027) 96.3 (94.9–97.3) 92.0 (89.7–93.8) 95.2 (85.6–98.5) 93.1 (74.6–98.4) 93.2 (89.1–95.8)
LDV/SOF 8 weeks* (n = 1,813) 96.4 (95.0–97.5) 93.1 (90.8–94.9) 96.4 (86.3–99.1) 92.0 (70.9–98.2) 95.3 (91.4–97.4)
LDV/SOF 12 weeks (n = 3,832) 95.5 (94.4–96.4) 95.2 (93.9–96.2) 93.8 (88.4–96.8) 93.9 (82.0–98.1) 93.4 (90.7–95.4)
*

LDV/SOF 8-week treatment in treatment-naive, patients without cirrhosis with viral load <6 million IU/mL.